Afficher la couverture 'Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases | Hümmert, Martin, W' en grand format
/5

0 avis

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

Archive ouverte

Hümmert, Martin, W | Bütow, Franziska | Tkachenko, Daria | Ayzenberg, Ilya | Pakeerathan, Thivya | Hellwig, Kerstin | Klotz, Luisa | Häußler, Vivien | Stellmann, Jan-Patrick | Warnke, Clemens | Goereci, Yasemin | Etgen, Thorleif | Luessi, Felix | Bronzlik, Paul | Gingele, Stefan | Lauenstein, Ann-Sophie | Kleiter, Ingo | Rommer, Paulus, S | Paul, Friedemann | Bellmann-Strobl, Judith | Duchow, Ankelien | Then Bergh, Florian | Pul, Refik | Walter, Annette | Pellkofer, Hannah | Kümpfel, Tania | Pompsch, Mosche | Kraemer, Markus | Albrecht, Philipp | Aktas, Orhan | Ringelstein, Marius | Senel, Makbule | Giglhuber, Katrin | Berthele, Achim | Jarius, Sven | Wildemann, Brigitte | Trebst, Corinna

Edité par CCSD ; American Academy of neurology -

International audience. Background and Objectives To evaluate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the life of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD). Methods This multicenter, cross-sectional study included data of 187 patients recruited from 19 different German and Austrian Neuromyelitis Optica Study Group (NEMOS) centers between July 2021 and March 2022. The effects of the pandemic on immunotherapeutic treatment and access to care, the possible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of vaccination against SARS-CoV-2 on disease incidence and relapse risk were assessed using a patient questionnaire. Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. Results One hundred eighty-seven patients (75% women; median age 47 [range 21-86] years; median disease duration 5.5 [range 0-67] years; median Expanded Disability Status Scale 2.0 [range 0-8.0];

Suggestions

Du même auteur

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Archive ouverte | Kümpfel, Tania | CCSD

International audience. This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmun...

Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Archive ouverte | Hümmert, Martin, W | CCSD

International audience. Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD). Objective: To assess cognitive performa...

Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD

Archive ouverte | Häußler, Vivien | CCSD

International audience. Recurrent attacks in neuromyelitis optica spectrum disorders (NMOSDs) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can lead to severe disability. We aimed to ana...

Chargement des enrichissements...